{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-065786","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.401121+00:00","generated_at":"2026-05-22T08:28:26.988539+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Korro Q1 net loss $23.4M; workforce reduction of 20%, cash runway into 2027","bullets":["Net loss $23.4M vs $19.6M YoY; collaboration revenue $2.6M from Novo Nordisk.","Cash, cash equivalents and marketable securities $139.0M, expected to fund operations into 2027.","Workforce reduction of approximately 20%; one-time restructuring charges ~$1.2M in Q2 2025.","Phase 1/2a REWRITE trial interim readout for KRRO-110 expected H2 2025; trial completion in 2026.","Expect to nominate second development candidate in 2025; Novo Nordisk cardiometabolic collaboration ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-065786","json":"https://secwatch.observer/filing/0000950170-25-065786.json","markdown":"https://secwatch.observer/filing/0000950170-25-065786.md","text":"https://secwatch.observer/filing/0000950170-25-065786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025065786/0000950170-25-065786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025065786/krro-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:28:26.988539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}